Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

Biotechnology • Healthcare • Cranford, NJ, United States • CTXR (NCM)

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

908 967 6677 11 Commerce Drive, Cranford, NJ 07016, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire
PR Newswire • Dec 23
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Yahoo Finance • Nov 12
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Quiver Quantitative • Dec 24
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire
PR Newswire • Dec 9
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Yahoo Finance • Oct 21

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Citius Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Citius Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Citius Pharmaceuticals, Inc. have?
Citius Pharmaceuticals, Inc. has approximately 23 employees.
What industry is Citius Pharmaceuticals, Inc. in?
Citius Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Citius Pharmaceuticals, Inc. a publicly traded company?
Yes, Citius Pharmaceuticals, Inc. is publicly traded under the ticker symbol CTXR on the NCM. The company has a market capitalization of approximately $0.02 billion.
Where is Citius Pharmaceuticals, Inc. headquartered?
Citius Pharmaceuticals, Inc. is headquartered in Cranford, NJ, United States at 11 Commerce Drive, Cranford, NJ 07016, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.